2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 939

Long-Term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome
Abstract Number: 940

NOD2-Associated Autoinflammatory Disease: Therapy and Outcomes
Abstract Number: 941

Relationship Between Colchine Plasma Level and Frequency of Familial Mediterranean Fever Attacks
Abstract Number: 942

Update in the Management of Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs Following Coccidioidomycosis
Abstract Number: 943

Development of an Internationally Agreed Minimal Dataset for Juvenile Dermatomyositis (JDM) for Clinical and Research Use
Abstract Number: 944

Activity of Type I and Type II Interferons in Dermatomyositis Skin Is Correlated with Characteristic Pathologic Features
Abstract Number: 945

Anti-Hmgcr Antibodies As Specific Marker for Immune Mediated Necrotizing Myopathies
Abstract Number: 946

Novel Tripartite Motif Proteins Linked to Membrane Integrity As Biomarkers of Dermatomyositis and Polymyositis
Abstract Number: 947

Cohesin Complex Is a New Myositis Autoantigen
Abstract Number: 948

Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response
Abstract Number: 949

The Metabolic Syndrome, Its Elements and Knee Osteoarthritis: The Framingham Osteoarthritis (OA) Study
Abstract Number: 950

In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients
Abstract Number: 951

Comparative Effectiveness of Tai Chi Versus Physical Therapy in Treating Knee Osteoarthritis: A Randomized, Single-Blind Trial
Abstract Number: 952

Cost-Effectiveness of Opioids for the Treatment of Knee Osteoarthritis: Impact of Chronic Opioid Use on Total Knee Arthroplasty Outcomes
Abstract Number: 953

Effectiveness of a Progressive Resistence Strength Programme on Hand Osteoarthritis: A Randomized Crontrolled Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].